Neurocrine Biosciences, Inc.
MX ˙ BMV ˙ US64125C1099
SecurityMX:NBIX / Neurocrine Biosciences, Inc.
InstitutionPerceptive Advisors Llc
ManagerJoseph Edelman
Latest Disclosed Ownership3,612,554 shares
Ownership 3.90%
Perceptive Advisors Llc ownership in NBIX / Neurocrine Biosciences, Inc.

2020-02-14 - Perceptive Advisors Llc has filed an SC 13G/A form with the Securities and Exchange Commission (SEC) disclosing ownership of 3,612,554 shares of Neurocrine Biosciences, Inc. (MX:NBIX). This represents 3.9 percent ownership of the company. In their previous filing dated 2019-02-14 , Perceptive Advisors Llc had reported owning 4,608,554 shares, indicating a decrease of -21.61 percent.

Perceptive Advisors Llc has a history of taking positions in derivatives of the underlying security (NBIX) in the form of stock options.

Institutional Ownership: 13D/G Filings

This table shows a history of the 13D/G filings made by the investor and/or investor group. Note that the share values in this table are not directly comparable to any numbers shown in the 13F table (if any).

File
Date
Effective
Date
Form Prev
Shares
Latest
Shares
ΔShares
(Percent)
Ownership
(Percent)
ΔOwnership
(Percent)
2020-02-14 2020-02-14 13G/A 4,608,554 3,612,554 -21.61 3.90 -23.53
2019-02-14 2019-02-14 13G/A 5,151,589 4,608,554 -10.54 5.10 -12.07
2018-02-14 2018-02-14 13G/A 4,657,589 5,151,589 10.61 5.80 9.43
2017-09-08 2017-09-08 13G 4,657,589 5.30
2015-02-17 2015-02-17 13G/A 3,565,267 4.69
2014-02-14 2014-02-14 13G/A 3,960,737 5.84
2013-02-14 2013-02-14 13G/A 4,212,137 6.33
2012-02-10 2012-02-10 13G 3,323,390 6.01

Important Note: One of the primary uses of the 13D/G filings is to evaluate the ability of a firm to control a company (ie, the "beneficial ownership"). To that end, firms are required to report not just direct holdings in companies, but indirect holdings that they control. For investment firms, these indirect holdings can include shares in funds they manage, advisory accounts, and in the case of activist campaigns, pledged votes. Therefore, share counts listed in 13D/G filings can differ significantly than share counts listed in 13F filings.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Institutional Put/Call Ratios
(Premium Subscription Required)

In addition to reporting standard equity and debt issues, institutions with more than 100MM assets under management must also disclose their put and call option holdings. Since put options generally indicate negative sentiment, and call options indicate positive sentiment, we can get a sense of the overall institutional sentiment by plotting the ratio of puts to calls. The chart to the right plots the historical put/call ratio for this instrument.

Using Put/Call Ratio as an indicator of investor sentiment overcomes one of the key deficiencies of using total institutional ownership, which is that a significant amount of assets under management are invested passively to track indices. Passively-managed funds do not typically buy options, so the put/call ratio indicator more closely tracks the sentiment of actively-managed funds.

MX:NBIX / Neurocrine Biosciences, Inc. Historical Put/Call Ratio
Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-29 2026-03-31 13F/A-1 NEUROCRINE BIOSCIENCES COM 64125C109 65,050 -266,000 -80.35 8,570 -81.75 0.1675
2026-05-15 2026-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 65,050 -266,000 8,570 0.1677
2026-02-17 2025-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 331,050 -119,000 -26.44 46,953 -25.68 0.8369
2025-11-14 2025-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 450,050 195,000 76.46 63,178 97.08 1.8243
2025-08-14 2025-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 255,050 155,000 154.92 32,057 189.72 1.1885
2025-08-06 2025-03-31 13F/A-1 NEUROCRINE BIOSCIENCES COM 64125C109 100,050 0 0.00 11,066 -18.97 0.3909
2025-05-15 2025-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 100,050 0 11,066 0.3899
2025-02-14 2024-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 100,050 -112,178 -52.86 13,657 -44.15 0.3764
2024-11-14 2024-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 212,228 -437,681 -67.34 24,453 -72.67 0.5173
2024-08-16 2024-06-30 13F/A-1 NEUROCRINE BIOSCIENCES COM 64125C109 649,909 -154,500 -19.21 89,473 -19.35 2.1550
2024-08-14 2024-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 649,909 -154,500 89,473 2.1306
2024-08-06 2024-03-31 13F/A-1 NEUROCRINE BIOSCIENCES COM 64125C109 804,409 533,615 197.06 110,944 210.95 1.9411
2024-05-15 2024-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 804,409 533,615 110,944 1.9268
2024-02-26 2023-12-31 13F/A-1 NEUROCRINE BIOSCIENCES COM 64125C109 270,794 111,552 70.05 35,680 99.17 0.7964
2024-02-14 2023-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 270,794 111,552 35,680 0.7961
2023-11-14 2023-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 159,242 59,192 59.16 17,915 89.89 0.5976
2023-08-24 2023-06-30 13F/A-1 NEUROCRINE BIOSCIENCES COM 64125C109 100,050 0 0.00 9,435 -6.84 0.2731
2023-08-14 2023-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 100,050 0 9,435 0.2735
2023-05-16 2023-03-31 13F/A-1 NEUROCRINE BIOSCIENCES COM 64125C109 100,050 0 0.00 10,127 -15.25 0.2990
2023-05-15 2023-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 100,050 0 10,127 0.2636
2023-02-14 2022-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 100,050 0 0.00 11,950 12.45 0.3356
2022-11-14 2022-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 100,050 -297,838 -74.85 10,626 -72.60 0.3084
2022-08-15 2022-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 397,888 2,249 0.57 38,786 4.57 1.2148
2022-05-16 2022-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 395,639 -87,368 -18.09 37,091 -9.84 0.7430
2022-05-04 2021-12-31 13F/A-2 NEUROCRINE BIOSCIENCES COM 64125C109 483,007 0 0.00 41,138 -11.20 0.6340
2022-04-13 2021-12-31 13F/A-1 NEUROCRINE BIOSCIENCES COM 64125C109 483,007 0 41,138 0.6351
2022-02-14 2021-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 483,007 0 41,138 0.6348
2021-12-03 2021-09-30 13F/A-1 NEUROCRINE BIOSCIENCES COM 64125C109 483,007 -328,825 -40.50 46,325 -41.37 0.6729
2021-11-15 2021-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 483,007 -328,825 46,325 0.6726
2021-08-17 2021-06-30 13F/A-1 NEUROCRINE BIOSCIENCES COM 64125C109 811,832 -130,000 -13.80 79,007 -13.74 1.0252
2021-08-16 2021-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 811,832 -130,000 79,007 1.0273
2021-08-13 2021-03-31 13F/A-2 NEUROCRINE BIOSCIENCES COM 64125C109 941,832 -957,383 -50.41 91,593 -49.69 1.1583
2021-06-10 2021-03-31 13F/A-1 NEUROCRINE BIOSCIENCES COM 64125C109 941,832 0 91,593 1.1553
2021-05-17 2021-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 941,832 -957,383 91,593 1.1575
2021-02-16 2020-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 1,899,215 350,500 22.63 182,040 22.24 1.9536
2020-11-16 2020-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 1,548,715 -592,695 -27.68 148,924 -43.00 2.1742
2020-08-17 2020-06-30 13F/A-1 NEUROCRINE BIOSCIENCES COM 64125C109 2,141,410 -921,853 -30.09 261,252 -1.46 4.2335
2020-08-14 2020-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 2,141,410 -921,853 261,252 4,243,508.0914
2020-05-18 2020-03-31 13F/A-1 NEUROCRINE BIOSCIENCES COM 64125C109 3,063,263 -549,291 -15.21 265,126 -31.72 6.9051
2020-05-15 2020-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 3,063,263 -549,291 265,126 6,905,128.5150
2020-02-19 2019-12-31 13F/A-1 NEUROCRINE BIOSCIENCES COM 64125C109 3,612,554 -447,346 -11.02 388,313 6.14 7.7136
2020-02-14 2019-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 3,612,554 -447,346 388,313 6,269,045.2401
2019-11-14 2019-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 4,059,900 36,038 0.90 365,837 7.68 9.8561
2019-08-14 2019-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 4,023,862 265,200 7.06 339,734 2.60 7.7956
2019-05-16 2019-03-31 13F/A-1 NEUROCRINE BIOSCIENCES COM 64125C109 3,758,662 -849,892 -18.44 331,138 5.00 9.3430
2019-05-15 2019-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 3,758,662 331,138
2019-02-14 2018-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 4,608,554 -168,700 -3.53 315,363 -46.31 12.0020
2018-11-14 2018-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 4,777,254 62,004 1.31 587,363 26.80 15.7056
2018-11-01 2018-06-30 13F/A-1 NEUROCRINE BIOSCIENCES COM 64125C109 4,715,250 -46,739 -0.98 463,226 17.30 12.1442
2018-08-14 2018-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 4,715,250 -46,739 463,226
2018-05-15 2018-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 4,761,989 -389,600 -7.56 394,912 -1.20 11.0612
2018-02-14 2017-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 5,151,589 360,000 7.51 399,712 36.13 13.2497
2017-11-14 2017-09-30 13F/A-1 NEUROCRINE BIOSCIENCES COM 64125C109 4,791,589 1,214,000 33.93 293,629 78.42 11.2178
2017-11-14 2017-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 4,791,589 293,629
2017-08-14 2017-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 3,577,589 211,059 6.27 164,569 12.90 8.2812
2017-05-15 2017-03-31 13F NEUROCRINE BIOSCIENCES SHARES COM 64125C109 3,366,530 50,007 1.51 145,771 13.57 8.3038
2017-05-02 2016-12-31 13F/A-3 NEUROCRINE BIOSCIENCES COM 64125C109 3,316,523 840,251 33.93 128,349 2.35 9.1271
2017-03-20 2016-12-31 13F/A-2 NEUROCRINE BIOSCIENCES COM 64125C109 3,316,523 0 128,349 9.1335
2017-03-09 2016-12-31 13F/A-1 NEUROCRINE BIOSCIENCES COM 64125C109 3,316,523 0 128,349 9.1335
2017-02-14 2016-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 3,316,523 128,349
2016-11-14 2016-09-30 13F NEUROCRINE BIOSCIENCES Common Stock 64125C109 2,476,272 -321,695 -11.50 125,398 -1.39 8.0942
2016-08-11 2016-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 2,797,967 77,000 2.83 127,167 18.17 8.8158
2016-05-16 2016-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 2,720,967 224,800 9.01 107,614 -23.79 9.4390
2016-02-16 2015-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 2,496,167 -446,800 -15.18 141,208 20.59 10.4473
2015-11-17 2015-09-30 13F/A-1 NEUROCRINE BIOSCIENCES COM 64125C109 2,942,967 -341,500 -10.40 117,101 -25.35 9.3527
2015-11-16 2015-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 2,942,967 117,101
2015-08-14 2015-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 3,284,467 -456,800 -12.21 156,866 5.59 9.4461
2015-05-15 2015-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 3,741,267 176,000 4.94 148,566 86.53 11.5453
2015-02-17 2014-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 3,565,267 -1,000,000 -21.90 79,648 11.34 6.6794
2014-11-17 2014-09-30 13F/A-2 NEUROCRINE BIOSCIENCES COM 64125C109 4,565,267 -34,600 -0.75 71,538 4.80 7.2406
2014-11-17 2014-09-30 13F/A-1 NEUROCRINE BIOSCIENCES COM 64125C109 4,565,267 0 71,538 7.6815
2014-11-14 2014-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 4,565,267 71,538
2014-08-14 2014-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 4,599,867 -19,500 -0.42 68,262 -8.22 6.6969
2014-05-15 2014-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 4,619,367 435,630 10.41 74,372 90.33 7.8148
2014-02-14 2013-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 4,183,737 -86,967 -2.04 39,076 -19.17 4.6932
2013-11-14 2013-09-30 13F/A-1 NEUROCRINE BIOSCIENCES COM 64125C109 4,270,704 -811,013 -15.96 48,344 -28.90 3.9236
2013-11-14 2013-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 4,270,704 48,344
2013-08-14 2013-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 5,081,717 5,081,717 67,993 6.8564
Disclosed Put Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share Price Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2015-05-15 2015-03-31 13F NEUROCRINE BIOSCIENCES COM Put 0 -100.00 0 -100.00 n/a n/a n/a
2015-02-17 2014-12-31 13F NEUROCRINE BIOSCIENCES COM Put 1,600,000 145.02 35,744 249.30 n/a n/a n/a
2014-11-17 2014-09-30 13F/A NEUROCRINE BIOSCIENCES COM Put 653,000 10,233 n/a n/a n/a
2014-11-17 2014-09-30 13F/A NEUROCRINE BIOSCIENCES COM Put 653,000 -59.19 10,233 -71.37 n/a n/a n/a
2014-11-14 2014-09-30 13F NEUROCRINE BIOSCIENCES COM Put 653,000 10,233 n/a n/a n/a
2014-02-14 2013-12-31 13F NEUROCRINE BIOSCIENCES COM Put 0 -100.00 0 -100.00 n/a n/a n/a
2013-11-14 2013-09-30 13F/A NEUROCRINE BIOSCIENCES COM Put 289,500 0.00 3,277 -18.36 n/a n/a n/a
2013-11-14 2013-09-30 13F NEUROCRINE BIOSCIENCES COM Put 289,500 3,277 n/a n/a n/a
2013-08-14 2013-06-30 13F NEUROCRINE BIOSCIENCES COM Put 4,014 n/a n/a n/a
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.